Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Outstanding (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Shares Outstanding data on record, last reported at $123.3 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 4.65% year-over-year to $123.3 million; the TTM value through Dec 2025 reached $123.3 million, up 4.65%, while the annual FY2025 figure was $123.3 million, 4.65% up from the prior year.
  • Shares Outstanding reached $123.3 million in Q4 2025 per ARQT's latest filing, up from $120.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $123.3 million in Q4 2025 and bottomed at $49.9 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $82.8 million, with a median of $61.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: rose 1.56% in 2023, then surged 89.14% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $50.3 million in 2021, then increased by 21.45% to $61.0 million in 2022, then skyrocketed by 58.57% to $96.8 million in 2023, then increased by 21.76% to $117.8 million in 2024, then rose by 4.65% to $123.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $123.3 million in Q4 2025, $120.3 million in Q3 2025, and $119.8 million in Q2 2025.